Literature DB >> 20048698

Specificity of the autologous neutralizing antibody response.

Penny L Moore1, Elin S Gray, Lynn Morris.   

Abstract

PURPOSE OF REVIEW: It has long been known that autologous neutralizing antibodies (AnAbs) exert pressure on the envelope of HIV, resulting in neutralization escape. However, recently, progress has been made in uncovering the precise targets of these potent early antibodies. RECENT
FINDINGS: AnAbs primarily target variable regions of the HIV-1 envelope, explaining the strain-specificity of these antibodies. Despite high neutralizing potential and cross-reactivity, anti-V3 antibodies do not contribute to autologous neutralization. The V1V2 is commonly immunogenic in early HIV-1 and simian human immunodeficiency virus infections, though the nature of these epitopes remains to be determined. In subtype C viruses, the C3 region is a neutralization target, possibly as a result of its more exposed and amphipathic structure. Autologous neutralization appears to be mediated by very few AnAb specificities that develop sequentially suggesting the possibility of immunological hierarchies for both binding and neutralizing antibodies. The role of AnAbs in preventing superinfection and in restricting virus replication is reexamined in the context of recent data.
SUMMARY: New studies have greatly contributed toward our understanding of the specificities mediating autologous neutralization and highlighted potential vulnerabilities on transmitted viruses. However, the contribution of AnAbs to the development of neutralization breadth remains to be characterized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20048698      PMCID: PMC3004050          DOI: 10.1097/COH.0b013e32832ea7e8

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  76 in total

1.  Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Authors:  Yongjun Guan; Mohammad M Sajadi; Roberta Kamin-Lewis; Timothy R Fouts; Anthony Dimitrov; Zhixin Zhang; Robert R Redfield; Anthony L DeVico; Robert C Gallo; George K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

2.  Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Authors:  Madhumita Mahalanabis; Pushpa Jayaraman; Toshiyuki Miura; Florencia Pereyra; E Michael Chester; Barbra Richardson; Bruce Walker; Nancy L Haigwood
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

3.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

4.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

5.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

6.  A method for identification of HIV gp140 binding memory B cells in human blood.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Bruce D Walker; Florencia Pereyra; Emily Cutrell; Michael S Seaman; John R Mascola; Richard T Wyatt; Hedda Wardemann; Michel C Nussenzweig
Journal:  J Immunol Methods       Date:  2008-12-25       Impact factor: 2.303

7.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

8.  Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Authors:  Katie L Davis; Frederic Bibollet-Ruche; Hui Li; Julie M Decker; Olaf Kutsch; Lynn Morris; Aidy Salomon; Abraham Pinter; James A Hoxie; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

9.  Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India.

Authors:  Smita S Kulkarni; Alan Lapedes; Haili Tang; S Gnanakaran; Marcus G Daniels; Ming Zhang; Tanmoy Bhattacharya; Ming Li; Victoria R Polonis; Francine E McCutchan; Lynn Morris; Dennis Ellenberger; Salvatore T Butera; Robert C Bollinger; Bette T Korber; Ramesh S Paranjape; David C Montefiori
Journal:  Virology       Date:  2009-01-23       Impact factor: 3.616

10.  Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Authors:  Yuxing Li; Krisha Svehla; Mark K Louder; Diane Wycuff; Sanjay Phogat; Min Tang; Stephen A Migueles; Xueling Wu; Adhuna Phogat; George M Shaw; Mark Connors; James Hoxie; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

View more
  43 in total

Review 1.  Prospects for an HIV vaccine: leading B cells down the right path.

Authors:  Susan Moir; Angela Malaspina; Anthony S Fauci
Journal:  Nat Struct Mol Biol       Date:  2011-12-05       Impact factor: 15.369

2.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

Authors:  Feng Gao; Mattia Bonsignori; Hua-Xin Liao; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Fangping Cai; Kwan-Ki Hwang; Hongshuo Song; Tongqing Zhou; Rebecca M Lynch; S Munir Alam; M Anthony Moody; Guido Ferrari; Mark Berrong; Garnett Kelsoe; George M Shaw; Beatrice H Hahn; David C Montefiori; Gift Kamanga; Myron S Cohen; Peter Hraber; Peter D Kwong; Bette T Korber; John R Mascola; Thomas B Kepler; Barton F Haynes
Journal:  Cell       Date:  2014-07-24       Impact factor: 41.582

5.  epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Authors:  Haili Tang; James E Robinson; S Gnanakaran; Ming Li; Eric S Rosenberg; Lautaro G Perez; Barton F Haynes; Hua-Xin Liao; Celia C Labranche; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

6.  HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.

Authors:  Ashley M Trama; M Anthony Moody; S Munir Alam; Frederick H Jaeger; Bradley Lockwood; Robert Parks; Krissey E Lloyd; Christina Stolarchuk; Richard Scearce; Andrew Foulger; Dawn J Marshall; John F Whitesides; Thomas L Jeffries; Kevin Wiehe; Lynn Morris; Bronwen Lambson; Kelly Soderberg; Kwan-Ki Hwang; Georgia D Tomaras; Nathan Vandergrift; Katherine J L Jackson; Krishna M Roskin; Scott D Boyd; Thomas B Kepler; Hua-Xin Liao; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2014-08-13       Impact factor: 21.023

7.  Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Authors:  Franco Pissani; Delphine C Malherbe; Harlan Robins; Victor R DeFilippis; Byung Park; George Sellhorn; Leonidas Stamatatos; Julie Overbaugh; Nancy L Haigwood
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

8.  Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.

Authors:  Elin S Gray; M Anthony Moody; Constantinos Kurt Wibmer; Xi Chen; Dawn Marshall; Joshua Amos; Penny L Moore; Andrew Foulger; Jae-Sung Yu; Bronwen Lambson; Salim Abdool Karim; John Whitesides; Georgia D Tomaras; Barton F Haynes; Lynn Morris; Hua-Xin Liao
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

Review 9.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

10.  Phenotypic Correlates of HIV-1 Macrophage Tropism.

Authors:  Kathryn T Arrildt; Celia C LaBranche; Sarah B Joseph; Elena N Dukhovlinova; William D Graham; Li-Hua Ping; Gretja Schnell; Christa B Sturdevant; Laura P Kincer; Macpherson Mallewa; Robert S Heyderman; Annelies Van Rie; Myron S Cohen; Serena Spudich; Richard W Price; David C Montefiori; Ronald Swanstrom
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.